Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET plus MTC)

被引：24
|
作者：
Hu, M. [1 ]
Subbiah, V. [2 ]
Wirth, L. J. [3 ]
Schuler, M. [4 ,5 ]
Mansfield, A. S. [6 ]
Brose, M. S. [7 ]
Curigliano, G. [8 ,9 ,10 ]
Leboulleux, S. [11 ]
Zhu, V. W. [12 ]
Keam, B. [13 ]
Matos, I. [14 ]
Lin, C-C. [15 ]
Adkins, D. [16 ]
Baik, C. S. [17 ]
Lopes, G. [18 ]
Godbert, Y. [19 ]
Sarker, D. [20 ]
Zhang, H. [21 ]
Turner, C. [21 ]
Taylor, M. [22 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Endocrine Neoplasia & Hormonal Disorders, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Invest Canc Therapeut, Houston, TX 77030 USA
[3] Harvard Med Sch, Massachusetts Gen Hosp, Dept Med, Boston, MA 02115 USA
[4] Univ Duisburg Essen, West German Canc Ctr, Essen, Germany
[5] Partner Site Univ Hosp Essen, German Canc Consortium DKTK, Essen, Germany
[6] Mayo Clin, Div Med Oncol, Rochester, MN USA
[7] Univ Penn, Abramson Canc Ctr, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA
[8] IRCCS, Dept Oncol, European Inst Oncol, Milan, Italy
[9] IRCCS, Dept Hematooncol, European Inst Oncol, Milan, Italy
[10] Univ Milan, Milan, Italy
[11] Gustave Roussy, Med Nucl & Endocrine Oncol, Villejuif, France
[12] Univ Calif Irvine, Dept Med, Orange, CA 92668 USA
[13] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
[14] Vall dHebron Inst Oncol, Early Drug Dev Unit, Barcelona, Spain
[15] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[16] Washington Univ, Sch Med, Div Oncol, St Louis, MO USA
[17] Univ Washington, Sch Med, Thorac Head & Neck Med Oncol, Seattle Canc Care Alliance, Seattle, WA USA
[18] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[19] Bergonie Inst Canc Ctr, Nucl Med, Bordeaux, France
[20] Kings Coll London, Dept Med Oncol, Guys Hosp, London, England
[21] Blueprint Med Corp, Cambridge, MA USA
[22] Providence Canc Inst, Earle A Chiles Res Inst, Portland, OR USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.1401
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1913O
引用
收藏
页码：S1084 / S1084
页数：1
相关论文
共 45 条
  • [1] Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET plus MTC)
    Keam, B.
    Hu, M. I.
    Subbiah, V.
    Wirth, L.
    Schuler, M.
    Mansfield, A. S.
    Brose, M. S.
    Curigliano, G.
    Leboulleux, S.
    Zhu, V. W.
    Matos, I.
    Adkins, D.
    Baik, C. S.
    Lopes, G.
    Godbert, Y.
    Sarker, D.
    Zhang, H.
    Turner, C. D.
    Taylor, M. H.
    Lin, C-C.
    ANNALS OF ONCOLOGY, 2020, 31 : S1413 - S1414
  • [2] Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion plus non-small cell lung cancer (NSCLC).
    Gainor, Justin F.
    Curigliano, Giuseppe
    Kim, Dong-Wan
    Lee, Dae Ho
    Besse, Benjamin
    Baik, Christina S.
    Doebele, Robert C.
    Cassier, Philippe Alexandre
    Lopes, Gilberto
    Tan, Daniel Shao-Weng
    Garralda, Elena
    Paz-Ares, Luis G.
    Cho, Byoung Chul
    Gadgeel, Shirish M.
    Thomas, Michael
    Liu, Stephen, V
    Clifford, Corinne
    Zhang, Hui
    Turner, Christopher D.
    Subbiah, Vivek
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [3] Registrational dataset from the phase 1/2 ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion plus non-small-cell lung cancer (NSCLC)
    Thomas, M.
    Griesinger, F.
    Schuler, M.
    Gainor, J. F.
    Curigliano, G.
    Kim, D. -W.
    Lee, D. H.
    Besse, B.
    Baik, C. S.
    Doebele, R. C.
    Cassier, P.
    Lopes, G.
    Tan, D. S. -W.
    Garralda, E.
    Paz-Ares, L.
    Cho, Chul B.
    Gadgeel, S. M.
    Liu, S. V.
    Turner, C. D.
    Subbiah, V.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 141 - 142
  • [4] Registrational Dataset from the Phase 1/2 ARROW Trial of Pralsetinib (BLU-667) in Patients with Advanced RET Fusion plus Non-Small-Cell Lung Cancer (NSCLC)
    Gainor, J. F.
    Curigliano, G.
    Kim, D. -W.
    Lee, D. H.
    Besse, B.
    Baik, C. S.
    Doebele, R. C.
    Cassier, P.
    Lopes, G.
    Tan, D. S. -W.
    Garralda, E.
    Paz-Ares, L.
    Cho, B. C.
    Gadgeel, S. M.
    Thomas, M.
    Liu, S. V.
    Clifford, C.
    Zhang, H.
    Turner, C. D.
    Subbiah, V.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S31 - S32
  • [5] Treatment with pralsetinib (formerly BLU-667), a potent and selective RET inhibitor, provides rapid clearance of ctDNA in patients with RET-altered non-small cell lung cancer (NSCLC) and medullary thyroid cancer (MTC)
    Lee, D. H.
    Subbiah, V.
    Gainor, J. F.
    Taylor, M. H.
    Zhu, V. W.
    Doebele, R. C.
    Lopes, G.
    Baik, C.
    Garralda, E.
    Gadgeel, S. M.
    Kim, D-W.
    Turner, C. D.
    Palmer, M.
    Miller, S.
    Curigliano, G.
    ANNALS OF ONCOLOGY, 2019, 30
  • [6] Pralsetinib in patients (pts) with advanced or metastatic RET-altered thyroid cancer (TC): Updated data from the ARROW trial.
    Mansfield, Aaron Scott
    Subbiah, Vivek
    Schuler, Martin H.
    Zhu, Viola Weijia
    Hadoux, Julien
    Brose, Marcia S.
    Curigliano, Giuseppe
    Wirth, Lori J.
    Garralda, Elena
    Adkins, Douglas
    Godbert, Yann
    Ahn, Myung-Ju
    Cassier, Philippe Alexandre
    Cho, Byoung Chul
    Lin, Chia-Chi
    Zhang, Hui
    Zalutskaya, Alena
    Barata, Teresa
    Scalori, Astrid
    Taylor, Matthew H.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [7] MATCHING ADJUSTED INDIRECT COMPARISON (MAIC) OF SELPERCATINIB VS CABOZANTINIB IN RET MUTATION-POSITIVE ADVANCED MEDULLARY THYROID CANCER (MTC)
    Jen, M. H.
    Kiiskinen, U.
    Khanal, M.
    Han, Y.
    Hess, L.
    Tian, W.
    Vickers, A.
    VALUE IN HEALTH, 2023, 26 (12) : S18 - S18
  • [8] Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion plus non-small cell lung cancer (NSCLC).
    Gainor, Justin F.
    Lee, Dae Ho
    Curigliano, Giuseppe
    Doebele, Robert Charles
    Kim, Dong-Wan
    Baik, Christina S.
    Tan, Daniel Shao-Weng
    Lopes, Gilberto
    Gadgeel, Shirish M.
    Cassier, Philippe Alexandre
    Taylor, Matthew H.
    Liu, Stephen V.
    Besse, Benjamin
    Thomas, Michael
    Zhu, Viola Weijia
    Zhang, Hui
    Clifford, Corinne
    Palmer, Michael
    Turner, Christopher D.
    Subbiah, Vivek
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] Updated efficacy and safety data from the phase I/II ARROW study of pralsetinib in patients (pts) with advanced RET fusion plus non-small cell lung cancer (NSCLC)
    Besse, B.
    Griesinger, F.
    Curigliano, G.
    Thomas, M.
    Subbiah, V.
    Baik, C. S.
    Tan, D. S. W.
    Lee, D. H.
    Garralda, E.
    Kim, D-W.
    Van Der Wekken, A. J.
    Gainor, J.
    Paz-Ares, L.
    Liu, S. V.
    Bowles, D. W.
    Zalutskaya, A.
    Ruf, T.
    Rahman, A.
    Chen, G.
    Mazieres, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1083 - S1084
  • [10] Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
    Subbiah, Vivek
    Hu, Mimi, I
    Wirth, Lori J.
    Schuler, Martin
    Mansfield, Aaron S.
    Curigliano, Giuseppe
    Brose, Marcia S.
    Zhu, Viola W.
    Leboulleux, Sophie
    Bowles, Daniel W.
    Baik, Christina S.
    Adkins, Douglas
    Keam, Bhumsuk
    Matos, Ignacio
    Garralda, Elena
    Gainor, Justin F.
    Lopes, Gilberto
    Lin, Chia-Chi
    Godbert, Yann
    Sarker, Debashis
    Miller, Stephen G.
    Clifford, Corinne
    Zhang, Hui
    Turner, Christopher D.
    Taylor, Matthew H.
    LANCET DIABETES & ENDOCRINOLOGY, 2021, 9 (08): : 491 - 501
12345